<DOC>
	<DOCNO>NCT02956122</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy GLASSIA add-on biopharmacotherapy standard-of-care steroid treatment first-line treatment participant acute GvHD low GI involvement .</brief_summary>
	<brief_title>A Phase 2/3 Study GLASSIA Treatment Acute GvHD</brief_title>
	<detailed_description />
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Alpha 1-Antitrypsin</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>1 . Male female participant age ≥18 year time screen 2 . Recipient hematopoietic stem cell transplantation ( HSCT ) 3 . The disease indication participant require HSCT must remission 4 . Acute graftversushost disease ( GvHD ) , include low GI involvement ( modify International Bone Marrow Transplant Registry ( IBMTR ) Severity Stage 1 4 [ &gt; 500 mL diarrhea/day ] ) , without organ system involvement Participants newly diagnose . Treatment methylprednisolone/systemic steroid must initiate within 72 hour prior first dose study treatment enrollment . 5 . Evidence myeloid engraftment ( absolute neutrophil count ≥0.5 x 10^9/L ) 6 . Lower GI GvHD manifest diarrhea must cause diarrhea rule ( eg , negative Clostridium difficile cytomegalovirus [ CMV ] infection oral magnesium administration ) 7 . Karnofsky Performance Score ≥50 % 8 . If female childbearing potential , participant present negative blood pregnancy test 9 . Females childbearing potential fertile male sexual partner must agree employ adequate contraception duration study . 10 . Males must use adequate contraception must donate sperm duration study . 11 . Participant willing able comply requirement protocol 1 . Participant manifestation chronic GvHD 2 . Participant acute/chronic GvHD overlap syndrome 3 . Participant whose GvHD develop donor lymphocyte infusion 4 . Participant myocardial infarction within 6 month prior enrollment New York Heart Association Class III IV heart failure , uncontrolled angina , severe uncontrolled ventricular arrhythmia electrocardiographic evidence acute ischemia active conduction system abnormality . Prior first dose study treatment , electrocardiogram ( ECG ) abnormality screen must document investigator medically relevant 5 . Participant evidence recurrent malignancy 6 . Participant venoocclusive disease ( ie , sinusoidal obstruction syndrome ) 7 . Participant receive GvHD treatment continue prophylaxis ( eg , cyclosporine and/or mycophenolate mofetil , etc ) corticosteroid therapy . In addition , participant receive first dose corticosteroid therapy acute GvHD low GI involvement 72 hour first dose study treatment eligible study 8 . Participant severe sepsis involve least 1 organ failure 9 . Participant seropositive positive nucleic acid test human immunodeficiency virus ( HIV ) 10 . Participant active hepatitis B C 11 . Participant participate another clinical study involve investigational product ( IP ) investigational device within 30 day prior enrollment schedule participate another clinical study involve IP investigational device course study 12 . If female , participant pregnant lactating time enrollment , plan become pregnant study 13 . Participant serious medical psychiatric illness likely interfere participation study 14 . Participant family member employee investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>